Back to discover

Protein / target

DNA gyrase subunit B

gyrBP0AES6Escherichia coli (strain K12)Swiss-Prot
30
Clinical trials
3
Drugs targeting

Protein at a glance

Biological role

ATP-dependent activity, acting on DNA

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner to maintain chromosomes in an underwound state.

View complete UniProt function annotation

DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner to maintain chromosomes in an underwound state (PubMed:12051842, PubMed:12051843, PubMed:1323022, PubMed:18642932, PubMed:186775, PubMed:19060136, PubMed:19965760, PubMed:20356737, PubMed:20675723, PubMed:22457353, PubMed:23294697, PubMed:23352267, PubMed:24386374, PubMed:25202966, PubMed:25849408, PubMed:3031051, PubMed:7811004, PubMed:8248233, PubMed:8621650, PubMed:9657678). This makes better substrates for topoisomerase 4 (ParC and ParE) which is the main enzyme that unlinks newly replicated chromosomes in E.coli (PubMed:9334322). Gyrase catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes (PubMed:22457352). Relaxes negatively supercoiled DNA in an ATP-independent manner (PubMed:337300). E.coli gyrase has higher supercoiling activity than other characterized bacterial gyrases; at comparable concentrations E.coli gyrase introduces more supercoils faster than M.tuberculosis gyrase, while M.tuberculosis gyrase has higher decatenation than supercoiling activity compared to E.coli (PubMed:22457352). E.coli makes 15% more negative supercoils in pBR322 plasmid DNA than S.typhimurium; the S.typhimurium GyrB subunit is toxic in E.coli, while the E.coli copy can be expressed in S.typhimurium even though the 2 subunits have 777/804 residues identical (PubMed:17400739). The enzymatic differences between E.coli gyrase and topoisomerase IV are largely due to the GyrA C-terminal domain (approximately residues 524-841) and specifically the GyrA-box (PubMed:16332690, PubMed:8962066)

Subcellular location

Cytoplasm
Domains and Gene Ontology detail (16)

Domains & features

Toprim

Gene Ontology

  • Cchromosome
  • Ccytoplasm
  • Ccytosol
  • CDNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complex
  • FATP binding
  • FATP-dependent activity, acting on DNA
  • FDNA binding
  • FDNA negative supercoiling activity
  • FDNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity
  • Fmetal ion binding
  • PDNA topological change
  • PDNA-templated DNA replication

804 aa · 90 kDa

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

View underlying pathways (2)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

3 medicines · 9 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Bacterial Infections3 medicines
Eye Infections3 medicines
Infections2 medicines
Acne Vulgaris1 medicine
Corneal Ulcer1 medicine
Gonorrhea1 medicine
Sinusitis1 medicine
Typhoid Fever1 medicine
Urinary Tract Infections1 medicine

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

3

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

Ofloxacin
Inhibitor

Bacterial DNA gyrase inhibitor

Indicated for Acne Vulgaris, Bacterial Infections, Corneal Ulcer, Eye Infections

Acts on a complex — shared with gyrA · 1 of 2 recorded protein targets — narrow recorded profile

Ciprofloxacin
Inhibitor

Bacterial DNA gyrase inhibitor

Indicated for Bacterial Infections, Eye Infections, Gonorrhea, Infections

Acts on a complex — shared with gyrA · 1 of 4 recorded protein targets

norfloxacin
Inhibitor

Bacterial DNA gyrase inhibitor

Indicated for Bacterial Infections, Eye Infections

Acts on a complex — shared with gyrA · 1 of 4 recorded protein targets

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

ACTIVE_NOT_RECRUITING · via Ciprofloxacin · NCT05100654

WITHDRAWN · via Ciprofloxacin · NCT03347461

UNKNOWN · via norfloxacin · NCT03506256

ClinicalTrials.gov via the drug-target graph.

What's happening now

12

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 3 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Label change2026-07-22

    Label change: CIPROFLOXACIN (ANDA076558)

    fda · regulatory · fda · via Ciprofloxacin

  2. Label change2026-07-22

    Label change: CIPROFLOXACIN (ANDA076794)

    fda · regulatory · fda · via Ciprofloxacin

  3. New publication2023-09-12
    Global diversity and antimicrobial resistance of typhoid fever pathogens: Insights from a meta-analysis of 13,000 <i>Salmonella</i> Typhi genomes.

    eLife · 2023 · 93 citations · Europe PMC · via Ciprofloxacin

  4. Label change2023-08-31

    Label change: CIPROFLOXACIN (ANDA076558)

    fda · regulatory · fda · via Ciprofloxacin

  5. Label change2023-08-31

    Label change: CIPROFLOXACIN (ANDA076558)

    fda · regulatory · fda · via Ciprofloxacin

  6. Label change2023-08-31

    Label change: CIPROFLOXACIN (ANDA076558)

    fda · regulatory · fda · via Ciprofloxacin

  7. Label change2023-08-31

    Label change: CIPROFLOXACIN (ANDA076558)

    fda · regulatory · fda · via Ciprofloxacin

  8. Label change2023-08-31

    Label change: CIPROFLOXACIN (ANDA076558)

    fda · regulatory · fda · via Ciprofloxacin

  9. Safety communication2014-12-11

    Drug Safety Update: Norfloxacin: restricted use in urinary infections

    mhra · safety · mhra · via norfloxacin

  10. New publication2012-02-01
    Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial.

    JAMA · 2012 · 48 citations · Europe PMC · via Ciprofloxacin

  11. New publication2011-09-01
    Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.

    Archives of pediatrics & adolescent medicine · 2011 · 162 citations · Europe PMC · via Ciprofloxacin

  12. New publication2007-06-01
    Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors.

    Journal of cataract and refractive surgery · 2007 · 548 citations · Europe PMC · via Ofloxacin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.